NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.69 +0.21 (+0.27%) GOLD FUTURES
2,322.10 -9.10 (-0.39%) DOW
38,870.51 +18.24 (+0.05%) Bitcoin GBP
50,529.99 -0.38 (-0.00%)
ERAS Jul 2024 2.500 call
| Previous close | 0.2000 |
| Open | 0.1000 |
| Bid | 0.1000 |
| Ask | 0.3000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1000 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 617 |
GlobeNewswireErasca to Present at the Bank of America Health Care Conference
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 15, 2024 at 4:20 pm Pacific Time and will also participate in one-on-one investo
- GlobeNewswire
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused
ZacksErasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
